The Expanding Treatment Armamentarium and Clinical Decision Making: ExteNET, DestinyBREAST-05, HER2CLIMB, and Other Emerging Trials
Dr. Tarantino discuss the integration of recent trial data into post-neoadjuvant treatment strategies, comparing adjuvant T-DM1 with pertuzumab plus trastuzumab.
EP: 1.Overview of HER2-Targeting Agents in Breast Cancer and Treatment Selection Approaches
EP: 2.APHINITY Trial: Pertuzumab for Patients with HER2+ Breast Cancer
EP: 3.KATHERINE: Adjuvant T-DM1 vs Trastuzumab for Residual Invasive HER2+ Breast Cancer
EP: 4.Exciting Developments in HER2+ Breast Cancer
EP: 5.Current Approaches to Treatment Sequencing in HER2+ Breast Cancer
EP: 6.Unmet Needs and Future Directions in HER2+ Breast Cancer
EP: 7.Risk Stratification and Treatment Selection in HER2+ Breast Cancer: The Current Treatment Landscape and NCCN Guideline Recommendations
EP: 8.Long-Term Pertuzumab Outcomes in HER2+ Breast Cancer: Insights from APHINITY 8-Year Data and NeoSphere Pooled Analysis
EP: 9.KATHERINE Trial: Long-Term Outcomes of T-DM1 vs Trastuzumab in HER2+ Breast Cancer with Residual Disease
EP: 10.The Expanding Treatment Armamentarium and Clinical Decision Making: ExteNET, DestinyBREAST-05, HER2CLIMB, and Other Emerging Trials
EP: 11.Unmet Needs and Future Directions in HER2+ Breast Cancer Management
Video content above is prompted by the following:
- How might these data factor into your treatment considerations post neoadjuvant treatment?
- When would you recommend adjuvant T-DM1 over adjuvant pertuzumab plus trastuzumab in this setting?
- With a growing number HER2-targeting agents available, how do you approach the decision-making process in your practice? Please comment on other trials investigating HER2 targeting agents?
- Trastuzumab
- Tucatinib
- Neratinib
- How do you evaluate and compare data from clinical trials for these agents?
- What are the factors you consider when selecting between HER2-targeted agents?
- What are your considerations for optimal sequencing of these therapies?
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
ADCs Demonstrate Superiority Vs Chemotherapy in Recurrent Breast Cancer
August 20th 2024During a Case-Based Roundtable® event, Reshma Mahtani, DO, discussed the importance of data from the TROPiCS-02 and TROPION-Breast01 trials of antibody-drug conjugates in patients with hormone receptor positive metastatic breast cancer.
Read More
